Asset Details
Do you wish to reserve the book?
High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
Do you wish to request the book?
High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
2016
Overview
The high-strength formulation of extrafine beclometasone dipropionate/formoterol fumarate (BDP/Form) 200/6 µg has been developed to step up inhaled corticosteroid treatment, without increasing the dose of the bronchodilator, in patients who are not controlled with previous therapies. Two clinical studies have evaluated efficacy of high-strength BDP/Form as compared with another high-dose fixed combination and BDP monotherapy. Overall, data show that BDP/Form 200/6 μg improves lung function and has beneficial effects on symptoms, use of rescue medication and asthma control, with an acceptable safety profile comparable with that of high-dose fluticasone propionate/salmeterol. Therefore, BDP/Form 200/6 μg could be considered as an effective and safe treatment for patients with asthma who are not adequately controlled with high doses of inhaled corticosteroid monotherapy or medium doses of inhaled corticosteroid/long-acting β2-agonist combinations.
Publisher
SAGE Publications,SAGE PUBLICATIONS, INC,SAGE Publishing
Subject
/ Adrenal Cortex Hormones - administration & dosage
/ Anti-Asthmatic Agents - administration & dosage
/ Anti-Asthmatic Agents - adverse effects
/ Asthma
/ Beclomethasone - administration & dosage
/ Beclomethasone - adverse effects
/ Bronchodilator Agents - administration & dosage
/ Dose-Response Relationship, Drug
/ Formoterol Fumarate - administration & dosage
/ Formoterol Fumarate - adverse effects
/ Humans
/ Inhalers
/ Reviews
